Macquarie Group Ceases to Be Substantial Holder in Australian Clinical Labs

Macquarie Group Limited ( (AU:MQG) ) has provided an update.

Macquarie Group Limited and its controlled entities have lodged a notice with Australian Clinical Labs Limited indicating that they have ceased to be a substantial holder in the pathology company. The filing, signed by company secretary Simone Kovacic and dated 9 March 2026, reflects changes in Macquarie’s relevant interests and associations in ACL’s voting securities, in line with disclosure obligations under Australia’s Corporations Act.

The notice lists Macquarie Group and a wide network of controlled corporate entities, underscoring the breadth of the group’s investment and holding structure behind the former substantial position. While specific transaction details are contained in annexures, the move signals that Macquarie has reduced its stake in Australian Clinical Labs below the substantial holding threshold, with potential implications for ACL’s share register composition and Macquarie’s capital allocation priorities.

The most recent analyst rating on (AU:MQG) stock is a Hold with a A$210.00 price target. To see the full list of analyst forecasts on Macquarie Group Limited stock, see the AU:MQG Stock Forecast page.

More about Macquarie Group Limited

Macquarie Group Limited is a global financial services provider headquartered in Sydney, operating across asset management, banking, advisory, and capital markets. Through various controlled entities, Macquarie manages investments and financing structures spanning infrastructure, renewable energy, real estate, and other alternative assets in key markets including Australia, Europe, Asia, and the Americas.

YTD Price Performance: -1.43%

Average Trading Volume: 711,862

Technical Sentiment Signal: Buy

Current Market Cap: A$73.21B

For an in-depth examination of MQG stock, go to TipRanks’ Overview page.